ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 735.5 USD | +0.57% |
|
-1.71% | +25.92% |
| 12:00pm | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
| Apr. 22 | Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates | RE |
Business Summary
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Number of employees: 43,000
Sales per Business
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Human Pharmaceutical Products
100.0
%
| 28,541 | 100.0 % | 34,124 | 100.0 % | +19.56% |
Sales per region
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
63.9
%
| 18,190 | 63.7 % | 21,791 | 63.9 % | +19.80% |
Europe
18.1
%
| 4,299 | 15.1 % | 6,175 | 18.1 % | +43.62% |
Other Foreign Countries
8.6
%
| 2,852 | 10.0 % | 2,946 | 8.6 % | +3.30% |
Japan
4.9
%
| 1,747 | 6.1 % | 1,673 | 4.9 % | -4.28% |
China
4.5
%
| 1,453 | 5.1 % | 1,540 | 4.5 % | +5.98% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-16 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
Alonzo Weems
CMP | Compliance Officer | - | 96-12-31 |
| Chief Tech/Sci/R&D Officer | 50 | 17-12-31 | |
| Corporate Officer/Principal | - | 04-12-31 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
Ronald DeMattos
PRN | Corporate Officer/Principal | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
Juan Luciano
BRD | Director/Board Member | 62 | 16-01-31 |
William Kaelin
BRD | Director/Board Member | 66 | 12-06-03 |
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Jamere Jackson
BRD | Director/Board Member | 54 | 16-09-30 |
| Director/Board Member | 52 | 11-12-11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 13-08-31 |
Karen Walker
BRD | Director/Board Member | 62 | 18-11-30 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 951,168,100 | 949,200,653 ( 99.79 %) | 402,000 ( 0.0423 %) | 99.79 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2,548,145 | 6.25% | 165,629,425 $ |
| 8,084,411 | 6.83% | 50,324,488 $ | |
PROQR THERAPEUTICS N.V. 16.55% | 13,371,562 | 16.55% | 30,620,877 $ |
| 4,000,000 | 9.40% | 26,840,000 $ | |
| 21,776,804 | 7.60% | 11,630,773 $ | |
AC IMMUNE SA 3.64% | 3,615,328 | 3.64% | 10,701,371 $ |
| 125,405 | 1.91% | 1,700,492 $ |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Eli Lilly SA
 Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The private company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Kinsale Financial Services
| |
ELI Lilly & Company (India) Pvt Ltd.
 ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Lilly Ventures Fund I LLC
 Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Export SA (Switzerland)
 Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Eli Lilly Group Pension Trustees Ltd.
 Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The private company is based in Basingstroke, UK. |
Financial Conglomerates
|
Eli Lilly (Suisse) SA
| |
Eli Lilly Vostok SA
| |
Eli Lilly Services India Pvt Ltd.
 Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The private company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Sector
Sales per region
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.46% | 659B | |
| +26.79% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.38% | 215B | |
| +7.61% | 210B | |
| -6.05% | 200B | |
| -8.79% | 149B | |
| -5.59% | 146B |
- Stock Market
- Equities
- LLY Stock
- Company Eli Lilly and Company
